187 Matching Annotations
  1. Jul 2025
  2. Oct 2023
  3. Mar 2023
  4. Feb 2023
  5. Sep 2022
    1. In short, the questions about Google’s behavior are not about free speech; they do, though, touch on other Amendments in the Bill of Rights. For example: The Fourth Amendment bars “unreasonable searches and seizures”; while you can make the case that search warrants were justified once the photos in question were discovered, said photos were only discovered because Mark’s photo library was indiscriminately searched in the first place. The Fifth Amendment says no person shall be deprived of life, liberty, or property, without due process of law; Mark lost all of his data, email account, phone number, and everything else Google touched forever with no due process at all. The Sixth Amendment is about the rights to a trial; Mark was not accused of any crime in the real world, but when it came to his digital life Google was, as I noted, “judge, jury, and executioner” (the Seventh Amendment is, relatedly, about the right to a jury trial for all controversies exceeding $20).

      Ben Thompson argues that questions about Google's behavior towards a false positive case of CSAM does not pertain to free speech or to the First Amendment. But it does pertain to other Amendments in the Bill of Rights.

    1. O’ then what news was for his som,

      the act of the neighbor telling the son is important. the son is then the character who saw Pickett and Carey with blood on their clothes, and accused them of the murder of his father.

  6. Aug 2022
  7. Jun 2022
  8. Apr 2022
    1. The Lancet. (2021, April 16). Quantity > quality? The magnitude of #COVID19 research of questionable methodological quality reveals an urgent need to optimise clinical trial research—But how? A new @LancetGH Series discusses challenges and solutions. Read https://t.co/z4SluR3yuh 1/5 https://t.co/94RRVT0qhF [Tweet]. @TheLancet. https://twitter.com/TheLancet/status/1383027527233515520

  9. Mar 2022
  10. Feb 2022
    1. Agarwal, A., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L., Leo, Y.-S., Macdonald, H., Zeng, L., Amin, W., Barragan, F. A., Bausch, F. J., Burhan, E., Calfee, C. S., Cecconi, M., Chanda, D., Dat, V. Q., Sutter, A. D., … Vandvik, P. O. (2020). A living WHO guideline on drugs for covid-19. BMJ, 370, m3379. https://doi.org/10.1136/bmj.m3379

  11. Jan 2022
  12. Dec 2021
  13. Nov 2021
  14. Oct 2021
  15. Sep 2021
  16. Aug 2021
    1. Madhi, S. A., Koen, A. L., Izu, A., Fairlie, L., Cutland, C. L., Baillie, V., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Aley, P. K., Bhikha, S., Hermanus, T., Horne, E., Jose, A., Kgagudi, P., Lambe, T., Masenya, M., … Kwatra, G. (2021). Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: An interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. The Lancet HIV, 0(0). https://doi.org/10.1016/S2352-3018(21)00157-0

  17. Jul 2021
  18. Jun 2021
  19. May 2021
    1. Gobeil, P., Pillet, S., Séguin, A., Boulay, I., Mahmood, A., Vinh, D. C., Charland, N., Boutet, P., Roman, F., Most, R. V. D., Perez, M. de los A. C., Ward, B. J., & Landry, N. (2021). Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older. MedRxiv, 2021.05.14.21257248. https://doi.org/10.1101/2021.05.14.21257248

    1. Eric Topol. (2021, February 17). New reports @NEJM today confirming some immune evasion of the B.1.351 variant (identified in South Africa) to both the mRNA vaccines, in vitro data @BioNTech_Group/@Pfizer and @moderna_tx. Less vaccine efficacy vs B.1.351 has been confirmed in clinical trials for 3 vaccines https://t.co/2N7eKDllso [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1362160675913568256

  20. Apr 2021
  21. Mar 2021
    1. Yufika, A., Wagner, A. L., Nawawi, Y., Wahyuniati, N., Anwar, S., Yusri, F., Haryanti, N., Wijayanti, N. P., Rizal, R., Fitriani, D., Maulida, N. F., Syahriza, M., Ikram, I., Fandoko, T. P., Syahadah, M., Asrizal, F. W., Aletta, A., Haryanto, S., Jamil, K. F., … Harapan, H. (2020). Parents’ hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia. Vaccine, 38(11), 2592–2599. https://doi.org/10.1016/j.vaccine.2020.01.072

  22. Feb 2021
    1. Dr Ellie Murray. (2020, December 3). Some really great resources & discussions in this thread. The tl;dr is (1) yes, the vaccine trials included some people who had previously had COVID; and (2) in general vaccination plans will include those who have previously been sick/infected. Thanks all! [Tweet]. @EpiEllie. https://twitter.com/EpiEllie/status/1334545373126389766

  23. Jan 2021
    1. Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.-J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., … Schuitemaker, H. (2021). Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2034201

  24. Dec 2020
    1. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

  25. Nov 2020
  26. Oct 2020
  27. Sep 2020
    1. Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., Pardo-Hernandez, H., Rochwerg, B., Lamontagne, F., Han, M. A., Liu, Q., Agarwal, A., Agoritsas, T., Chu, D. K., Couban, R., Darzi, A., Devji, T., Fang, B., Fang, C., … Brignardello-Petersen, R. (2020). Drug treatments for covid-19: Living systematic review and network meta-analysis. BMJ, 370. https://doi.org/10.1136/bmj.m2980

  28. Aug 2020
    1. Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31605-6

    1. Horby, P., Mafham, M., Linsell, L., Bell, J. L., Staplin, N., Emberson, J. R., Wiselka, M., Ustianowski, A., Elmahi, E., Prudon, B., Whitehouse, A., Felton, T., Williams, J., Faccenda, J., Underwood, J., Baillie, J. K., Chappell, L., Faust, S. N., Jaki, T., … Landray, M. J. (2020). Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. MedRxiv, 2020.07.15.20151852. https://doi.org/10.1101/2020.07.15.20151852

  29. Jul 2020
    1. Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S. P., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fonter-Garfias, C., Shi, P.-Y., Tuereci, O., Tompkins, K. R., Walsh, E. E., … Jansen, K. U. (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. MedRxiv, 2020.06.30.20142570. https://doi.org/10.1101/2020.06.30.20142570

    1. Meyer, B., Torriani, G., Yerly, S., Mazza, L., Calame, A., Arm-Vernez, I., Zimmer, G., Agoritsas, T., Stirnemann, J., Spechbach, H., Guessous, I., Stringhini, S., Pugin, J., Roux-Lombard, P., Fontao, L., Siegrist, C.-A., Eckerle, I., Vuilleumier, N., & Kaiser, L. (2020). Validation of a commercially available SARS-CoV-2 serological immunoassay. Clinical Microbiology and Infection, 0(0). https://doi.org/10.1016/j.cmi.2020.06.024

    1. Corbett, K. S., Edwards, D., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. BioRxiv, 2020.06.11.145920. https://doi.org/10.1101/2020.06.11.145920

  30. Jun 2020
    1. Chen, L., Zhang, Z., Fu, J., Feng, Z., Zhang, S.-Z., Han, Q.-Y., Zhang, X., Xiao, X., Chen, H.-M., Liu, L.-L., Chen, X.-L., Lan, Y.-P., Zhong, D.-J., Hu, L., Wang, J.-H., Yu, X.-H., She, D.-Y., Zhu, Y.-H., & Yin, Z.-Y. (2020). Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: A prospective open-label randomized controlled study. MedRxiv, 2020.06.19.20136093. https://doi.org/10.1101/2020.06.19.20136093

    1. Sbidian, E., Josse, J., Lemaitre, G., Mayer, I., Bernaux, M., Gramfort, A., Lapidus, N., Paris, N., Neuraz, A., Lerner, I., Garcelon, N., Rance, B., Grisel, O., Moreau, T., Bellamine, A., Wolkenstein, P., Varoquaux, G., Caumes, E., Lavielle, M., … Audureau, E. (2020). Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: A cohort study of 4,642 in-patients in France. MedRxiv, 2020.06.16.20132597. https://doi.org/10.1101/2020.06.16.20132597

  31. May 2020
  32. Apr 2020
    1. REE decreased approximately 15% when TSH increased between 0.1 and 10 mU/L.

      The individual change in REE to a given change in dose varied radically. The dose change was only 50 mcg, which seemed to change TSH about half what they've calculated for 15% REE change. That is to say, it looks like a 50 mcg dose reduction will only raise TSH from 1.0 to 5.0, not to 10.0. This is my personal guesstimate, and will need to be properly calculated from other studies. My point is merely that 50 mcg will not cause the full 15% REE increase. Additionally, the response to 50 mcg may depend on initial TSH.

      It looks like TSH changes that remained hyperthyroid (i.e. bellow 1.0) had little effect on REE. This might be because the body is maintaining thyroid status, or that REE is more like an on/off switch. However, this only covers relatively small changes in thyroxine dose.

      It is unclear how supraphysiological doses effect REE. It seems likely that the ten times greater dose (500 mcg) used for depression would significantly increase REE.

  33. Mar 2020
    1. The addition of supraphysiologic doses of L-T4 (300 mcg per day) to an otherwise stable medication regimen of standard treatments resulted in a significant decline in depression scores during the 6-week, double-blind treatment phase. At endpoint (week 6), the mean HamD score showed a group difference of 3.7 points in favor of L-T4. Such difference is generally considered to be clinically meaningful in a short-term treatment trial for major depression. NICE used a 3.0-point difference in HamD change scores as a criterion of clinical significance.27

      This is consistent with the open label data. The dose is also similar. Combining this placebo-controlled trial with the three open-label supraphysiological thyroxine studies that I've seen, that is sufficient for me to conclude efficacy. Namely, combining with Pfeiffer et al (350 mcg), Rudas et al (235 mcg) and Bauer et al (482 mcg)

      I would like to see if this study mentions nonresponders. Those three other studies found roughly a 50% response rate. Thus, the effect size in responders may be twice as significant.

  34. Feb 2020
  35. Jan 2020
    1. The authors demonstrated an inverse correlation between TSH and REE with a change of 15% for a TSH ranging from 0.1 to 10 μIU/mL. Of interest, free T4 remained within the normal range in all of the study volunteers. Nonetheless, the changes in REE with different LT4 doses were demonstrated in every patient [46].

      Thus, a 15% expected increase would be reasonable for a euthyroid subject such as myself. However, since T3 reduces weight compared to T4, it is possible the weight loss indicates greater energy expenditure.

    1. CONCLUSION: This randomized double-blind, placebo-controlled clinical trial demonstrated that Amla could reduce frequencies of heartburn and regurgitation and improve heartburn and regurgitation severity in patients with NERD.

      Is there anything it can't do? I have noted, however, that larger doses cause nausea for me. That is, 3 or more grams on an empty stomach. I just vomited after taking 7.5 grams before my meal, but I have not yet established the causal link. It is the largest amount I've ever taken at one time. I suspect that it may have contributed significantly, but that it was also one out of half a dozen factors.

  36. Nov 2019
  37. Mar 2019
  38. Nov 2018
  39. Feb 2018
  40. Jan 2018
  41. Jun 2016
  42. May 2016
    1. Mistakes are not just opportunities for learning; they are, in an important sense, the only opportunity for learning or making something truly new. Before there can be learning, there must be learners. There are only two non-miraculous ways for learners to come into existence: they must either evolve or be designed and built by learners that evolved. Biological evolution proceeds by a grand, inexorable process of trial and error — and without the errors the trials wouldn’t accomplish anything.
  43. Jun 2015
    1. Get an estimated price for posting a parcel or letter within Australia or overseas. Prefer an easy, fixed cost on sending a parcel in Australia? View our prepaid satchels starting from $8.25